A

Aspen Neuroscience ASPE

$12.59

−7.49%

Nov 13

1W

1M

Activities

Neurodegeneration drugs

Sign in to see the AI's note on Aspen Neuroscience, Inc. Common Stock.

Posts

Aspen Neuroscience

5d ago · 5% stake

ARCH Venture declares 12.9% of Aspen Neuroscience, held for investment

ARCH Venture Fund X and its affiliated funds hold 12.9% of Aspen Neuroscience after its IPO and say they hold the shares for investment, with no present plans.

Neurodegeneration drugs

Aspen Neuroscience

1w ago · 5% stake

OrbiMed declares 12.3% of Aspen Neuroscience after its IPO, for investment only

OrbiMed, a healthcare investor, holds 12.3% of newly listed Aspen Neuroscience, and says it bought the shares as an investment, not to take control.

See all posts →

About Aspen Neuroscience, Inc. Common Stock

Aspen Neuroscience is a clinical-stage biotech in San Diego developing cell therapies made from a patient's own stem cells. Its lead candidate, sasineprocel, aims to replace the dopamine-producing neurons lost in Parkinson's disease and is in an early-stage trial. It has no products on sale and no revenue, and it funds its research with money raised from investors, most recently its October 2026 IPO.